direct anticoagulant

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

StrokeAtrial FibrillationCarcinoma, Non-Small-Cell LungVenous ThromboembolismAnticoagulationHead Injury

150 competitors in Stroke

#DrugCompanyPhaseTrials

1

direct anticoagulant

Bayer

Phase 3

32

Zometa

Pfizer

Preclinical

13

Savella

AbbVie

Preclinical

14

Proamatine

Takeda

Preclinical

—5

Repatha

Amgen

Preclinical

—6

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

17

Zantac 150

CChattem

Preclinical

18

Alka-Seltzer

AAbbott

Preclinical

19

Haldol

DDePuy Orthopaedics

Preclinical

110

Anticoagulant

Bayer

Preclinical

1Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Stroke3 trials

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

Completed·Bayer··NCT02470767·792 enrolled

DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial

Not yet recruiting·PPopulation Health Research Institute·Phase 1·NCT07011095·100 enrolled

OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial

Active, not recruiting·UUniversity College, London·N/A·NCT03759938·3,648 enrolled

Head Injury1 trial

Mild Head Injury, Antiplatelets, and Anticoagulants

Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT04741334·2,127 enrolled

Hip Fracture1 trial

Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention

Not yet recruiting·MMcMaster University·Phase 3·NCT07228663·100 enrolled

Anticoagulation1 trial

Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus

Active, not recruiting·—·Phase 3·NCT05825573·340 enrolled

Atrial Fibrillation1 trial

An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers

Completed·Bayer··NCT02559232·247 enrolled

5 more indications

Uterine Bleeding1 trial

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

Completed·Johnson & Johnson··NCT04394234·961,985 enrolled

Low Molecular Weight Heparin1 trial

Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery

Active, not recruiting·—·Phase 1·NCT06913595·100 enrolled

Venous Thromboembolism1 trial

Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients

Recruiting·PPeking Union Medical College Hospital··NCT06194617·300 enrolled

Anticoagulant1 trial

Periprocedural Direct Oral Anticoagulant Management

Completed·FFundación para la Investigación del Hospital Clínico de Valencia··NCT03182218·1,100 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

Recruiting·Johnson & Johnson·Phase 2·NCT05498428·520 enrolled

Details

Drug Info

Related News